BioSpace News Archive

Career Advice

Employer Insights: The Top 3 Things That Define the Best Candidate

Do you know what employers in the life sciences industry value when it comes to hiring the best candidate? They look for the qualities mentioned in the article.

March 6, 2019
·
3 min read
·
Porschia Parker
Deals

Bristol-Myers Squibb Strikes Back! Response to Critics of Celgene Deal

Bristol-Myers Squibb announced its bid to acquire Celgene on January 3, 2019. However, the deal hit a snag. Bristol-Myers Squibb is now fighting back, making efforts to sell the deal to its shareholders.

March 6, 2019
·
3 min read
·
Mark Terry
Drug Development

Moderna’s Q4 Shows a Company Bursting at the Seams With Activity

Coming off its record-breaking initial public offering (IPO) in December, where it raised $604.3 million, Moderna released its fourth-quarter financials, outlining an ambitious company buzzing with activity.

March 6, 2019
·
3 min read
·
Mark Terry
Policy

BioSpace’s Global Biopharma Roundup: March 7

Biotech and pharma companies from across the globe share data and news in a weekly roundup.

March 6, 2019
·
4 min read
·
Alex Keown
Almac Group Announces Almac One™ – A Unified Clinical Trial Supply Solution

Unique solution offers sponsors a streamlined approach to the global supply chain

March 6, 2019
·
2 min read
Deals

Medtronic Announces the Early Results of its Cash Tender Offers for Certain Outstanding Debt Securities Issued by Medtronic, Inc. and Covidien International Finance S.A.

Medtronic plc today announced that, pursuant to the previously-announced cash tender offers

March 6, 2019
·
10 min read
FDA

Janssen’s Controversial Esketamine Treatment for Depression OK’ed by FDA, the First in Nearly 50 Years

Janssen believes the treatment works by restoring synaptic connections in brain cells in individuals with major depressive disorder.

March 6, 2019
·
2 min read
·
Alex Keown
Business

Gilead Exec Takes Over Helm of New Glenmark Innovation Business

Glenmark Pharmaceuticals’ new innovation business has its chief executive officer. Alessandro Riva, head of oncology therapeutics and cell therapy at Gilead Sciences will take over the reins of the new innovation company as its CEO on April 2. Riva is the first named executive of the new company.

March 6, 2019
·
3 min read
·
Alex Keown
Drug Development

Vertex Triple Combination CF Drugs Hit the Mark in Phase III Trials

This morning, Boston-based Vertex said its triple-combination treatment VX-445, tezacaftor and ivacaftor resulted in statistically significant improvements in lung function in two late-stage cystic fibrosis trials.

March 6, 2019
·
3 min read
·
Alex Keown
Drug Development

Alnylam’s Givosiran Looks Positive Overall in Phase III Trial for Rare Disease

Despite releasing positive data on its Phase III ENVISION trial, Alnylam stock dropped 7.5 percent. Although not completely clear why, the drop may be related to a high percentage of serious adverse events observed in the trial.

March 6, 2019
·
3 min read
·
Mark Terry